Media Thread, page-515

Winsolo: "Biggest market with huge demand."

Winsolo/others: "Winsolo" makes reference to CHINA as a market for use of cancer drugs. But China is also involved with Cancer RESEARCH efforts.
I am not SURE if anything in this respect has already been posted here - but assume that NOT? Therefore, let me QUOTE the following:
QUOTE
Novartis dives into Beigene's Cancer Immunotherapy
(Published by REUTERS on January 12th, 2021)
Swiss drugmaker Novartis paid US$ 650 million to snag an immuno-oncology drug from BeiGene Ltd, the latest Western drugmaker turning to China for must-have assets to fill holes in their cancer portfolios. Novartis CEO Vas Narasimhan's move, which could bring US$ 1.55 billion in milestone payments and royalties for BeiGene, is also an about-face from comments two years ago when he raised data quality and innovation worries as barriers to Big Pharma's Chinese M&A dreams. Novartis will co-develop BeiGene's tislelizumab, an anti-PD-1 antibody similar to Keytruda from Merck and Opdivo from Bristol-Myers Squibb which help the immune system attack cancer and which have reaped billions of dollars in sales. Pfizer's US$ 200 million investment in China's CStone Pharmaceuticals in September, also targeting an immuno-oncology asset, is another such deal. Susanne Schaffert, Novartis's cancer
area head, pledged to use tislelizumab "to develop transformative combination therapies for patients", she said.
END OF QUOTE

Personally, I just WISH that one of the BIG PHARMA companies will also feel that their "MUST-HAVE ASSETS TO FILL HOLES in their CANCER PORTFOLIOS" will select something from IMUGENE's large portfolio before too much longer - and with substantial funding, of course! Time will tell.

Sorry for my a bit long POST today... and it is not even FRIDAY yet...!

All the best to all IMU holders and buyers.
Wishing you all 'down under' (or wherever else you are living) way early on a pleasant weekend coming up from tomorrow evening onwards!
Stay safe, stay healthy!

wasa